Mold on mattresses poses a genuine risk of infection to infants
A federal warning letter to Happiest Baby Inc. has placed one of the most trusted names in infant sleep under regulatory scrutiny, raising questions about what it means to market safety to the most vulnerable. The FDA found that the maker of the $1,700 SNOO bassinet sold unevaluated sleep sack sizes without required review and allowed mold and unsanitary conditions to persist on products placed directly against newborns. In the long arc of consumer trust, this moment asks whether premium price and devoted following are sufficient substitutes for rigorous accountability.
- The FDA's formal warning letter signals that Happiest Baby Inc. crossed a significant regulatory line by introducing new sleep sack sizes without required safety evaluation.
- Mold discovered on SNOO mattresses and their covers transforms what might have been a paperwork violation into a direct, physical threat to infant health.
- The company's disclosure that it severed ties with a refurbishment partner two years ago over poor cleaning practices suggests leadership knew sanitation was a vulnerability — yet the problem persisted.
- Happiest Baby has pledged cooperation with the FDA, but the path forward remains uncertain, with recalls and further enforcement both still on the table.
- Parents who paid $1,700 for a device marketed as a sleep solution are now left without clear guidance on whether their units are safe to use.
The FDA has issued a formal warning letter to Happiest Baby Inc., the company behind the SNOO — a $1,700 automated bassinet that rocks infants to sleep and has earned a devoted following among exhausted parents. The agency's findings go beyond paperwork: inspectors documented mold on SNOO mattresses and their covers, along with stains and soiling on equipment, conditions that pose a genuine infection risk to the newborns these products are designed to comfort.
The violations also include the sale of extra-small and extra-large sleep sacks — the fabric pouches that secure infants inside the device — without submitting them for the required safety and effectiveness evaluation. The FDA was unambiguous in its letter, stating that the company had significantly modified the SNOO by introducing these unevaluated sizes.
Happiest Baby responded by pledging to work with the FDA to address the findings. The company also revealed it had ended a relationship with a refurbishment partner two years earlier, citing inadequate cleaning practices — a detail that suggests awareness of sanitation problems in its supply chain, even if that awareness proved insufficient.
The warning letter does not automatically require a recall, but one remains possible depending on the company's response and any further investigation. For parents currently using a SNOO, the letter leaves urgent and unanswered questions about the safety of their specific units and what, if any, corrective guidance the company will provide.
The FDA has sent a formal warning letter to Happiest Baby Inc., the company behind the SNOO, one of the most recognizable baby products on the market. The agency alleges that the manufacturer sold sleep sacks in two new sizes—extra-small and extra-large—without submitting them for safety and effectiveness evaluation. It's a significant breach of regulatory protocol for a device marketed to newborns and infants.
But the unauthorized product sizes are only part of the problem. FDA inspectors also documented unsanitary conditions at the company's facilities, including stains and soiling on equipment, and more troublingly, mold discovered on SNOO mattresses and their covers. These findings carry real weight: mold and contaminated surfaces pose a genuine risk of infection to the infants who sleep on them. The SNOO itself is a $1,700 automated bassinet designed to soothe babies by rocking them when they cry, with infants secured in fabric sleep sacks that clip to the device's sides. It's a premium product with a devoted following among parents seeking help with infant sleep.
In its warning letter, the FDA was direct: "There is evidence that your firm has significantly changed or modified the SNOO Smart Sleeper by introducing two new sizes of sleep sacks." The agency listed the violations plainly—the unevaluated sleep sacks, the unsanitary conditions, the mold. Each one represents a failure in the company's responsibility to ensure the safety of products used by some of the most vulnerable consumers.
Happiest Baby responded to CBS News with a statement emphasizing its willingness to cooperate. The company said it is "committed to working with the FDA to address the matters in their letter." It also disclosed that two years prior, it had ended a business relationship with a partner company that handled refurbishment of SNOO units, citing inadequate cleaning practices. That detail suggests the company was aware of sanitation issues in its supply chain and took action—though apparently not comprehensively enough to prevent the problems the FDA found.
The warning letter itself does not automatically trigger a recall, though that remains a possibility depending on how the company responds and what further investigation reveals. For parents who have purchased a SNOO, the letter raises immediate questions about whether their units are safe, whether they should be cleaned or inspected, and whether the company will issue guidance or take corrective action. The FDA's next move will depend on Happiest Baby's response and whether the company can demonstrate that it has addressed the root causes of both the unauthorized product modifications and the manufacturing and sanitation failures.
Citações Notáveis
There is evidence that your firm has significantly changed or modified the SNOO Smart Sleeper by introducing two new sizes of sleep sacks— FDA warning letter to Happiest Baby Inc.
We are committed to working with the FDA to address the matters in their letter— Happiest Baby Inc. statement to CBS News
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that the company introduced new sleep sack sizes without FDA approval?
Because the FDA requires safety testing for any meaningful change to a medical device. A different size means different fit, different pressure points, different risk profiles for an infant. You can't just assume what works for one size works for another.
And the mold—how serious is that?
Mold on a surface a baby sleeps on every night is serious. It's not just unpleasant. It can cause respiratory issues, skin infections, other complications in infants whose immune systems are still developing. That's why the FDA specifically flagged it as a potential infection risk.
The company says it ended a partnership two years ago over cleaning issues. Does that suggest they knew about the problem?
It suggests they identified a problem in their supply chain and tried to fix it. But the FDA found mold and stains after that decision, which means either the new arrangement didn't solve it, or there were other sources of contamination they hadn't addressed.
What happens now?
The company has to respond to the FDA with a plan. They might issue recalls, they might improve their manufacturing processes, they might do both. Parents who own SNOOs are in a waiting period—they don't yet know if their units are affected or what they should do.
Is this a sign the company is fundamentally unsafe?
It's a sign of lapses in quality control and oversight. The SNOO itself isn't inherently unsafe—it's been used by thousands of families. But this letter shows the company didn't maintain the standards it should have. Whether that's fixable or systemic, we don't know yet.